InstructorOleg Karaduta

M.D., Volgograd State Medical University, Russia

Lab: (501) 686-5842 – Biomedical Research Center 1; B434
Fax: (501) 686-8169

My primary area of research is microbiome-host interactions and their role in human disease. Currently, in Dr. Zybaylov’s laboratory we study function of the gut microbiome in chronic kidney disease and looking into prebiotics as a potential disease management strategy. In our studies we aim to identify specific cecal bacteria and cecal, blood, and urinary peptides that are associated with decreases in the rate of loss of kidney function caused by a resistant starch diet. In collaboration with Dr. John Arthur’s group (division of Nephrology, UAMS) we have developed a novel multy-omics pipeline to analyze microbiome-host interactions1, published an in-depth literature review2, and also confirmed that resistant starch slows the deterioration of kidney function in the murine surgical model of CKD3.

1. Zybailov BL, Glazko GV, Rahmatallah Y, Andreyev DS, McElroy T, Karaduta OK, Byrum SD, Orr L, Tackett AJ, Mackintosh SG, Edmondson RD, Kieffer DR, Martin RJ, Adams SH, Vaziri ND, and Arthur JM (2019). Metaproteomics Reveals Potential Mechanisms by which Dietary Resistant Starch Supplementation Attenuates Chronic Kidney Disease Progression in Rats. PLOS ONE.

2. Hobby GP, Karaduta OK, Singh M, Zybailov BL and Arthur JM (2019). Chronic Kidney Disease and the Gut Microbiome. Am J Physiol Renal Physiol. doi:10.1152/ajprenal.00298.2018.

3. Karaduta OK, Dvanajscak Z, Arthur JM, Mackintosh SG, Orr LM, and Zybaylov BL,
(2019) Resistant starch slows down progression of CKD in 5/6 nephrectomy mouse model. JASN, manuscript under preparation.